In addition to neutralizing VEGF-A, inhibitors that can competitively bind to the kinase domains of VEGFR have been reported to also exhibit beneficial effects in in vivo models of inflammatory skin disorders [17,30]. The gene discussed is KDR; the disease is inflammatory skin disease.